BiotechTube

Camrelizumab plus TP + TP

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Squamous Cell Carcinoma

Conditions

Oral Squamous Cell Carcinoma

Trial Timeline

Nov 21, 2023 → Oct 1, 2026

NCT ID
NCT05798793

About Camrelizumab plus TP + TP

Camrelizumab plus TP + TP is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Oral Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05798793. Target conditions include Oral Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05798793Phase 3Recruiting

Competing Products

20 competing products in Oral Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
AG013OragenicsPhase 2
44
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Micafungin + FluconazoleAstellas PharmaPhase 3
77
micafungin + caspofunginAstellas PharmaPhase 3
77
Erlotinib + PlaceboAstellas PharmaPhase 3
77
AmifostineSun PharmaceuticalApproved
85
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
23
Teriparatide 20 mcgEli LillyPhase 3
77
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
85
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
85
galantamine hydrobromideJohnson & JohnsonPhase 2
52
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
52
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
33
DurvalumabAstraZenecaPhase 1/2
41
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85